海外の治験の状況【臨床研究情報ポータルサイト】

海外の治験の状況「1」での検索結果

絞り込み

251件の検索結果

Authorised
A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression during or After Aromatase Inhibitor Therapy
WOMEN WITH ER-POSITIVE AND HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAS DIDEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY MedDRA version: 17.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
Australia, Austria, Bulgaria, Canada, Colombia, Czech Republic, France, Germany, Greece, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Turkey, United States
2015-01-12

Authorised
Long term continuous infusion ch14.18/CHO plus s.c. aldesleukin (IL-2) randomised
High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Primary refractory patients with stage 4 disease with at least two lines of treatment prior to HDT/SCT, causing a delay from diagnosis to SCT of over 9 months • Relapse after primary stage 4 disease • Disseminated relapse after primary localized neuroblastoma ;Therapeutic area: Diseases [C] - Cancer [C04]
Australia, Austria, Belgium, France, Germany, Hong Kong, Ireland, Israel, Italy, Poland, Spain, United Kingdom
2010-09-24

Authorised
A phase III, open-label, multiarm study to assess the efficacy of immunotherapy together with standard of care in patients diagnosed with extensive stage Small-Cell Lung Cancer
First-line patients with extensive disease (Stage IV) small-cell lung cancer (SCLC) MedDRA version: 20.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
Argentina, Austria, Brazil, Bulgaria, China, Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukraine, United States
2017-01-26

Authorised
A Phase 2 clinical study evaluating safety and efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis (PBC) without adequate response or intolerance to Ursodeoxycholic Acid (UDCA).
Primary Biliary Cholangitis (PBC) MedDRA version: 20.1 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000004871 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
Australia, Austria, Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom, United States
2018-05-24

Authorised
A Phase 2 clinical study evaluating safety and efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis (PBC) without adequate response or intolerance to Ursodeoxycholic Acid (UDCA).
Primary Biliary Cholangitis (PBC) MedDRA version: 20.1 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000004871 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
Australia, Austria, Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom, United States
2018-05-16

Authorised
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 20.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Australia, Canada, Denmark, Estonia, New Zealand, Poland, Sweden, United States
2018-02-16

Authorised
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 19.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Argentina, Australia, Brazil, Canada, Denmark, Estonia, France, Germany, New Zealand, Poland, Romania, Russian Federation, Spain, Sweden, United States
2016-01-29

Authorised
A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease
Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000016693 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
2015-11-18

進捗状況

実施責任機関の所在地